Welcome to our dedicated page for Decibel Cannabis news (Ticker: DBCCF), a resource for investors and traders seeking the latest updates and insights on Decibel Cannabis stock.
Decibel Cannabis Company Inc. (DBCCF, TSXV: DB) generates frequent news related to its branded cannabis products, financial performance, and international expansion. The company describes itself as a consumer-focused cannabis producer known for premium cannabis and extract manufactured products, with brands such as General Admission, Qwest, and Vox sold across Canada and into global markets.
News coverage for Decibel often includes quarterly and annual financial results, where the company reports net revenue, gross margin before fair value adjustments, and non-GAAP measures such as Adjusted EBITDA, Adjusted Net Income or Loss, Free Cash Flow, and Adjusted Free Cash Flow. These releases also discuss trends in net Canadian recreational sales and international sales, as well as management’s commentary on balance sheet strength and covenant compliance.
Investors and followers can also expect updates on corporate transactions and strategic initiatives, including the acquisition and integration of AgMedica, which added an EU-GMP certified facility and expanded Decibel’s international platform. Additional news items highlight export contracts and regulatory developments that affect the timing and scale of international shipments.
Product and brand announcements form another important category of Decibel news. Examples include the launch and performance of General Admission Liquid Diamond vapes in multiple Canadian provinces, and the expansion of the General Admission brand into Israel through a supply and trademark license agreement for dried medical cannabis flower. Governance and capital markets updates, such as stock option grants and results of shareholder meetings, are also reported.
By following this news feed, readers can track how Decibel’s branded cannabis strategy, financial metrics, and international activities evolve over time, based solely on the company’s own public disclosures.
Decibel Cannabis Company (OTCQB: DBCCF) entered a conditional agreement to sell its Creston, British Columbia property for approximately $2,500,000 and will consolidate the Creston cultivation facility into its Battleford, Saskatchewan site.
The company said proceeds will repay part of its term debt, the transaction aims to generate $4 million in annual cost savings, is expected to close in April 2026, and is intended to improve production efficiency and strengthen the balance sheet.
Decibel Cannabis Company (OTCQB: DBCCF) granted an aggregate of 11,537,223 stock options effective after market close on February 10, 2026. Each Option is exercisable for one common share at $0.10 per share, the TSXV closing price on February 10, 2026.
The grant is a normal-course, long-term compensation and retention measure. Options vest in three equal annual installments on Jan 1, 2027, 2028 and 2029 and expire on Feb 10, 2031. The company operates cultivation and processing facilities across Canada and sells branded products domestically and beginning international expansion.
Decibel Cannabis (OTCQB: DBCCF) closed a $61 million credit package with ATB Financial, comprising a $40M first lien term, $10M revolver (with $3M available at close) and an $11M second lien term. Maturities were extended to February 2030, and 2026 payment obligations were reduced by $5M. Management said the financing improves free cash flow, removes near-term material maturities, maintains a debt/EBITDA ratio below 2.0x, and supports corporate development and international growth.
Decibel Cannabis Company (OTCQB: DBCCF) reported results of its annual and special meeting held on December 11, 2025. Shareholders approved all items voted on.
Key outcomes: the board size was fixed at four directors and Shawn Dym, Nadia Vattovaz, Jakob Ripshtein, and Benjamin Sze were elected; MNP LLP was appointed auditor; the 2025 Stock Option Plan was reapproved; and shareholders authorized a potential share consolidation up to 50-to-1, although the company said it currently has no intention to effect the consolidation.
Decibel Cannabis (OTCQB: DBCCF) reported Q3 2025 net revenue of $32.9M, up 37% YoY, driven by domestic recreational sales of $24.5M and international sales of $8.4M (AgMedica contribution $7.8M). Gross margin before fair value adjustments was 47% (down from 53% in Q3 2024). Adjusted EBITDA was $7.3M (+40% YoY) and adjusted net income was $3.8M. Free cash flow was $1.5M. Management revised 2025 guidance to ~$115M net revenue and ~$24M Adjusted EBITDA, citing German import permitting delays, a B.C. distribution disruption, and contract fee re‑structuring.
Decibel Cannabis Company (OTCQB: DBCCF) will report its third quarter 2025 financial results pre-market on November 19, 2025. The company will host a live conference call at 10:00 a.m. MST that day; Canadian dial-in is 1-800-715-9871, U.S. dial-in is 1-888-880-3330, conference ID 1629404. Investors can find more information at www.decibelcc.com.
Decibel describes itself as a consumer-focused cannabis company with brands including General Admission, Qwest, and Vox. Following the AgMedica acquisition in Q4 2024, Decibel added an EU-GMP-certified facility and now operates three cultivation facilities plus a processing and manufacturing center to support global distribution.
Decibel Cannabis Company (OTCQB: DBCCF) reported strong Q2 2025 financial results, with net revenue reaching $29.8 million, up 35% year-over-year. The growth was primarily driven by the successful integration of AgMedica, which contributed $5.4 million in total sales.
Key highlights include international sales of $6.1 million, a 176% increase quarter-over-quarter, and net Canadian recreational sales of $23.7 million, up 7% year-over-year. The company achieved an Adjusted EBITDA of $6.3 million, representing a 60% increase, and Free Cash Flow of $2.2 million.
The company's gross margin before fair value adjustments improved to 47% from 42% in Q2 2024, while Adjusted Net Income reached $3.4 million, translating to earnings per share of $0.01.
[ "Net revenue increased by 35% year-over-year to $29.8 million", "International sales grew significantly to $6.1 million, up 176% quarter-over-quarter", "Gross margin improved to 47% from 42% year-over-year", "Adjusted EBITDA increased 60% to $6.3 million", "Free Cash Flow improved by $4.3 million to reach $2.2 million", "Successful integration of AgMedica acquisition contributing $5.4 million in sales" ]Decibel Cannabis Company (DBCCF) has announced its Q4 and full-year 2024 results, along with 2025 guidance. The company reported Q4 net revenue of $25.3 million (+0.4% YoY) and Adjusted EBITDA of $5.2 million (+4% YoY). The recent acquisition of AgMedica contributed $3.4 million in net revenue during Q4 2024.
For 2025, Decibel projects net revenue of $130 million, Adjusted EBITDA of $25 million, and Adjusted Free Cash Flow of $20 million. The company expects to expand its export presence from 7 to 9 markets. AgMedica, with its EU-GMP certified facility, is anticipated to contribute $30 million in net revenue and $4 million in EBITDA in 2025.
Q4 highlights include international sales of $3.4 million (+141% YoY), gross margin improvement to 49% (from 46%), and Free Cash Flow of $2.2 million (+18% YoY). The company notes Q1 2025 may be softer due to international shipment timing but expects significant growth from Q2 2025.
Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF) has signed a supply agreement and trademark license agreement with Keren Tirk to distribute General Admission branded medical cannabis flower in Israel. The initial shipment is expected in Q2 2025, targeting the mainstream segment of the Israeli medical cannabis market.
This expansion marks a significant milestone for Decibel, leveraging its domestic success to establish General Admission as a globally recognized brand. The company, which historically focused on premium price points, sees this as an opportunity to address larger volume opportunities in mainstream product segments. Following its Q4 2024 acquisition of AgMedica Biosciences, Decibel now operates with an EU-GMP certified facility, three cultivation facilities, and a processing and manufacturing center.